Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Neoplasms × Istiratumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Pancreatic Neoplasms 1 Insulin-Like Growth Factor I, Resistance To 1 Fibromatosis, Gingival, 2 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 616 130-nm albumin-bound paclitaxel 174 Fluorouracil 170 Oxaliplatin 155 Albumin-Bound Paclitaxel 138 Leucovorin 121 Capecitabine 120 Irinotecan 104 Radiotherapy 89 Taxes 77 pembrolizumab 73 Cisplatin 70 Erlotinib Hydrochloride 65 Radiosurgery 61 Bevacizumab 50 Nivolumab 49 Cyclophosphamide 46 Magnetic Resonance Spectroscopy 45 Drug Therapy 44 folfirinox 39 Specimen Handling 37 Docetaxel 37 Cetuximab 36 irinotecan sucrosofate 35 S 1 (combination) 34 Biopsy 33 Blood Specimen Collection 31 Pancreaticoduodenectomy 29 Paclitaxel 29 Radiation 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02399137 2018-09-18

CARRIE

Merrimack Pharmaceuticals

Phase 2 Completed

Gastrointestinal

Fibromatosis, Gingival, 2, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡